Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue SUPPL. 1, 2001, Pages

  Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD20; Monoclonal antibody; Non Hodgkin lymphoma; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RITUXIMAB; YTTRIUM;

B CELL LYMPHOMA; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; METHODOLOGY; RADIOIMMUNOTHERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CLINICAL TRIALS; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 0002631056     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100312     Document Type: Article

References (24)

1. Czuczman M, Grillo-López A, White C, Saleh M, Gordon L, LoBuglio A, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268
2. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP (1998) Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246
3. DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF (1999) 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 40:302
4. Gordon L, White C, Witzig T, Flinn I, Czuczman M, Wiseman G, Spies S, Olejnok T, Zhang C, Grillo-López A (1999) Zevalin (IDEC-Y2B8) radioimmunotherapy of Rituximab refractory follicular non-Hodgkin's lymphoma (NHL): interim results. Blood 94 [Suppl 1]:91a
5. Gordon L, Wiseman G, Witzig T, Murray J, Czuczman M, Joyce R, Bartlett N, Multani P, Grillo-Lopez A (2000) Zevalin induces transient neutropenia and B-cell depletion but does not induce clinically significant hypogammaglobulinemia nor serious infection risk. Proc Am Soc Clin Oncol 19:23a
6. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459
7. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974
8. Kaminski M, Gribbin T, Estes J, Ross C, Regan D, Zasadny K, Tamminen J, Kison P, Tuck M, Fisher S, Petry N, Wahl R (1998) I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc Am Soc Clin Oncol 17:2a
9. Kaminski M, Estes J, Zasadny K, Francis I, Ross C, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl R (2000) Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259
10. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457
11. Kreitman R, Wilson W, White J, Stetler-Stevenson M, Jaffe E, Giardina S, Waldmann T, Pastan I (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622
12. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270
13. Maloney D, Smith B, Appelbaum F (1996) The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 88:637a
14. McLaughlin P, Grillo-López A, Link B, Levy R, Czuczman M, Williams M, Heyman M, Bence-Bruckler I, White C, Cabanillas F, Jain V, Ho A, Lister J, Wey K, Shen D, Dallaire B (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825
15. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336
16. Press O, Eary J, Liu S, Petersdorf S, Bush S, Durack L, Martin P, Maloney D, Matthews D, Fisher D, Gooley T, Appelbaum F, Bernstein I (1998) A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas. Proc Am Soc Clin Oncol 17:3a
17. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO (2000) Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymph 38:91
18. Wiseman G, White C, Erwin W, Lamonica D, Kornmehl E, Silverman D, Witzig T, Gordon L, White M, Belanger R, Grillo-Lopez A (1999) Zevalin biodistribution and dosimetry estimated normal organ absorbed radiation doses are not affected by prior therapy with rituximab. Blood 94 [Suppl 1]:92a
19. Wiseman G, White C, Stabin M, Witzig T, Spies S, Silverman D, Raubitschek A, Janakiraman N, Gutheil J, Schilder R, Gordon L, Emmanouilides C, Berlfein J, Grillo-López A (2000) Phase I/II 90Y-Zevalin (yttrium90 ibritumomab tiuxefan (IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766
20. Wiseman G, White C, Sparks R, Erwin W, Podoloff D, Lamonica D, Bartlett N, Parker J, Dunn W, Spies S, Belanger R, Witzig T, Leigh B (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol (in press)
21. Witzig T, White C, Gordon L, Murray J, Wiseman G, Czuczman M, Pohlman B, Padre N, Grillo-López A (1999) Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to Rituximab immunotherapy for B-cell NHL: report of interim results. Blood 94 [Suppl 1]:631a
22. Witzig T, White C, Gordon L, Schilder R, Wiseman G, Rimmer A, Parker E, Grillo-López A (1999) Reduced-dose Zevalin radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of a phase II trial. Blood 94 [Suppl 1]:92a
23. Witzig T, White C, Wiseman G, Gordon L, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder R, Spies S, Silverman D, Parker E, Grillo-López A (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 positive B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793
24. Witzig T, Leigh B, Gordon L, Murray J, Wiseman G, Czuczman M, Pohlman B, Grillo-Lopez A, White C (2000) Interim results from a prospective randomized controlled trial comparing Zevalin radioimmunotherapy to rituximab immunotherapy for B-cell non-Hodgkin's lymphoma: resistance to prior chemotherapy vs response rate. Proc Am Soc Clin Oncol 19:29a